Pro-Dex (PDEX) Q1 2027 earnings summary

Executive summary

• Q1 FY2027 net sales rose 11% YoY to $20.560M; operating income increased to $3.515M, while net income fell to $3.048M from $4.680M, partly reflecting lower unrealized investment gains.

• Medical-device demand, especially next-generation orthopedic handpieces and CMF drivers, drove sales growth; lower repair revenue partly offset gains.

• Management expects to ship Monogram validation units later in FY2027.

Financial highlights

• Net sales were $20.560M versus $18.530M YoY; gross profit was $6.857M versus $5.367M.

• Net income was $3.048M versus $4.680M; diluted EPS was $0.92 versus $1.40.

• Operating cash flow was $6.5M versus $2.3M; cash and cash equivalents ended the quarter at $11.8M, up from $8.2M at June 30, 2026.

Outlook and guidance

• Backlog was $43.1M at September 30, 2026, with $42.4M scheduled for delivery during the remainder of FY2027; backlog excludes some revenue expected under existing contracts.

• Existing cash, receivables and expected operating cash flow are expected to fund requirements for at least 12 months; the $11M revolving facility is available if needed.

• Management expects similar sales volumes of the largest customer’s next-generation and legacy handpieces for the rest of FY2027, subject to supplier shipment timing.

• Monogram validation-unit shipments are expected later in FY2027, with work underway alongside Monogram and Zimmer Biomet teams.